Type 1 Diabetes

$50B+
Estimated Research Spending
50+
Years of Focused Cure Research
2 years
Maximum Onset Delay Achieved
0
Cures Approved

The Numbers

Type 1 diabetes is an autoimmune disease in which the immune system destroys the insulin-producing beta cells of the pancreas. Over $50 billion has been invested in research. Over 50 years of focused effort has been directed at cure development. The disease remains incurable.

Insulin, discovered in 1921, kept patients alive for 100+ years. It is not a cure. It is a management tool. The patient remains dependent on external insulin administration for life. Patients still die from Type 1 diabetes. The disease still progresses unchanged.

Insulin Discovery 1921
JDRF Founded 1970
Cure Approvals Since JDRF Launch 0
Teplizumab Maximum Effect 2 year delay

Promises vs. Reality

1921
Reality: Insulin discovered. Transforms Type 1 from fatal within months to lifelong management disease. Not a cure.
1970
Promise: JDRF founded with explicit mission: find a cure for Type 1 diabetes.
2000
Reality: Edmonton Protocol published. Islet cell transplantation works but requires lifelong immunosuppression. Cure remains elusive.
2010
Promise: Stem cell research accelerates. Regenerative medicine approaching. Cure projected for 2020.
2022
Reality: Teplizumab approved. First drug to delay disease onset. Delays progression by approximately 2 years. Does not prevent or cure.
2024
Promise: New beta cell regeneration approaches in trials. Immune tolerance research expanding. Cure timeline remains undefined.

Current Research Status

Type 1 diabetes research pursues multiple pathways: beta cell regeneration from stem cells, immune tolerance through regulatory T cell expansion, transplantation with better immunosuppression protocols, and early intervention with immune-modulating drugs like teplizumab.

None have produced a cure. The fundamental barrier remains unchanged: the immune system continues to attack beta cells regardless of whether cells are regenerated, transplanted, or derived from stem cells. Stopping the autoimmune attack without destroying the immune system's ability to fight infection is an unsolved problem.

Active Clinical Trials 80+
Phase III Trials 8
Years Since Last Major Approval 2 years
Cure Status No change

Sources & Methodology

Data compiled from NIH, peer-reviewed endocrinology literature, FDA approval records, and clinical trial registries.

Primary Sources

  • U.S. National Institutes of Health -- Type 1 Diabetes Research Funding (RePORT Database)
  • FDA Center for Drug Evaluation and Research -- Teplizumab approval documentation (2022)
  • ClinicalTrials.gov -- Type 1 Diabetes Active Trials Registry
  • New England Journal of Medicine -- Edmonton Protocol publication (2000)
  • Diabetes Care Journal -- Beta Cell Regeneration Research Reviews
  • JDRF Research Roadmap -- Current and Historical Research Priorities
  • Lancet -- Teplizumab efficacy and delay mechanism analysis (2023)